Mutagenic Impurity Risk Evaluation – Technologies to Assist in Stepwise Approach to Assessment.
Posted on June 1st, 2020
*Picture taken in February before social distancing measures were put in place.
Free webinar Thursday, June 18, 3:00 PM – 4:30 PM BST: Mutagenic Impurity Risk Evaluation – Technologies to Assist in Stepwise Approach to Assessment.
We’ve long been collaborating with a number of pharmaceutical companies on the measurement of Nitrosamines.
Since hosting April’s The Anatune Nitrosamine Forum 2020, we’ve continued working with Andrew Teasdale of AstraZeneca who asked us to partner on his upcoming webinar: Mutagenic Impurity Risk Evaluation – Technologies to Assist in Stepwise Approach to Assessment.
As we discussed at the forum, solving the issue of false positives is key in this context -particularly with regards to Nitrosamines – and automation has a big part to play in reducing the potential for sample contamination. Furthermore, since robots can perform the complex sample preparation ‘the same time every time’, automation greatly improves the accuracy and precision of results obtained. As automation specialists, it was a no brainer for us to get involved.
The webinar will look at some of the technology available to enable a consistent and thorough approach, including control options, sample preparation and service providers.
Andrew will be presenting the webinar and as the author of the ICH Safety Guidelines and tutor on: Practical management of impurities and development of effective and comprehensive control strategies – It’s fair to say that he’s the best possible person for the job.
For a more detailed rundown on what to expect and to register for this free webinar, click here.